Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's innovative medicine division reported revenues of $15.20 billion for the second quarter of 2025, exceeding consensus expectations, supported by strong growth in immunology and oncology. The company's management raised its fiscal year 2025 sales guidance to $93.2–$93.6 billion, driven by operational strength and favorable currency impacts, indicating a robust outlook for growth in the second half of the year and into 2026. Additionally, MedTech revenues reached $8.54 billion, surpassing expectations across all segments, underpinned by innovations and strategic pricing actions contributing to a resilient performance.

Bears say

Johnson & Johnson's financial outlook remains negative due to several fundamental challenges impacting its revenue growth across divisions. The company is facing significant risks from its pharmaceutical pipeline, with potential underperformance from newer product launches and an anticipated decline in sales from established drugs due to patent expirations, potentially resulting in total revenues falling below $57 billion by 2025. Additionally, competitive pressures in the MedTech segment and ongoing litigation costs may disrupt profitability, further complicating the company's growth trajectory in the coming years.

JNJ has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 15 analysts, JNJ has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.